GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Hisun Pharmaceutical Co Ltd (SHSE:600267) » Definitions » EV-to-EBIT

Zhejiang Hisun Pharmaceutical Co (SHSE:600267) EV-to-EBIT : 16.60 (As of May. 22, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Zhejiang Hisun Pharmaceutical Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zhejiang Hisun Pharmaceutical Co's Enterprise Value is ¥13,854 Mil. Zhejiang Hisun Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ¥835 Mil. Therefore, Zhejiang Hisun Pharmaceutical Co's EV-to-EBIT for today is 16.60.

The historical rank and industry rank for Zhejiang Hisun Pharmaceutical Co's EV-to-EBIT or its related term are showing as below:

SHSE:600267' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.03   Med: 30.99   Max: 290.45
Current: 16.6

During the past 13 years, the highest EV-to-EBIT of Zhejiang Hisun Pharmaceutical Co was 290.45. The lowest was 11.03. And the median was 30.99.

SHSE:600267's EV-to-EBIT is ranked worse than
50.14% of 698 companies
in the Drug Manufacturers industry
Industry Median: 16.39 vs SHSE:600267: 16.60

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Zhejiang Hisun Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2025 was ¥13,710 Mil. Zhejiang Hisun Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ¥835 Mil. Zhejiang Hisun Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 6.09%.


Zhejiang Hisun Pharmaceutical Co EV-to-EBIT Historical Data

The historical data trend for Zhejiang Hisun Pharmaceutical Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Hisun Pharmaceutical Co EV-to-EBIT Chart

Zhejiang Hisun Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.89 23.34 18.81 118.14 14.80

Zhejiang Hisun Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 136.50 114.93 105.50 14.80 16.43

Competitive Comparison of Zhejiang Hisun Pharmaceutical Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Hisun Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Hisun Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Hisun Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zhejiang Hisun Pharmaceutical Co's EV-to-EBIT falls into.


;
;

Zhejiang Hisun Pharmaceutical Co EV-to-EBIT Calculation

Zhejiang Hisun Pharmaceutical Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=13853.690/834.596
=16.60

Zhejiang Hisun Pharmaceutical Co's current Enterprise Value is ¥13,854 Mil.
Zhejiang Hisun Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥835 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Hisun Pharmaceutical Co  (SHSE:600267) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Zhejiang Hisun Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=834.596/13709.82688
=6.09 %

Zhejiang Hisun Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2025 was ¥13,710 Mil.
Zhejiang Hisun Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥835 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Hisun Pharmaceutical Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Zhejiang Hisun Pharmaceutical Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Hisun Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 46 Waisha Road, Jiaojiang District, Zhejiang Province, Taizhou, CHN, 318000
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
Executives
Yu Shun Bing Supervisors
Jin Hong Shun senior management
Lu Xing Hai senior management
Zhang Zhen Ying senior management
Jiang Guo Ping Director
Yang Zhi Qing senior management
Du Jia Qiu senior management
Chen Xiao Hua Directors, senior managers
Li Yan Directors, senior managers
Zhao Lei senior management
Shen Xi Fei Director
Zhang Wei senior management
Bai Hua Director
Chen Li Fei Supervisors
Hu Liang Bin senior management

Zhejiang Hisun Pharmaceutical Co Headlines

No Headlines